Cryogenic detectors for particle physics

École thématiqu

Testing the Special Relativity Theory with Neutrino interactions

A recent measurement of neutrino velocity by the OPERA experiment and prediction of energy loss of superluminal neutrino via the pair creation process $\nu\to \nu e^+e^-$ stimulated a search of isolated $e^+e^-$ pairs in detectors with good tracking capability traversed by a large flux of high energy neutrino like NOMAD. NOMAD has already searched for similar topologies. These results can be reinterpreted to provide stringent limits on special relativity violating parameters separately for each $\nu$ species.Comment: 3 pages, 3 figures, 1 table Accepted by EPL (Europhysics Letters

New hadrons as ultra-high energy cosmic rays

Ultra-high energy cosmic ray (UHECR) protons produced by uniformly distributed astrophysical sources contradict the energy spectrum measured by both the AGASA and HiRes experiments, assuming the small scale clustering of UHECR observed by AGASA is caused by point-like sources. In that case, the small number of sources leads to a sharp exponential cutoff at the energy E<10^{20} eV in the UHECR spectrum. New hadrons with mass 1.5-3 GeV can solve this cutoff problem. For the first time we discuss the production of such hadrons in proton collisions with infrared/optical photons in astrophysical sources. This production mechanism, in contrast to proton-proton collisions, requires the acceleration of protons only to energies E<10^{21} eV. The diffuse gamma-ray and neutrino fluxes in this model obey all existing experimental limits. We predict large UHE neutrino fluxes well above the sensitivity of the next generation of high-energy neutrino experiments. As an example we study hadrons containing a light bottom squark. These models can be tested by accelerator experiments, UHECR observatories and neutrino telescopes.Comment: 17 pages, revtex style; v2: shortened, as to appear in PR

Extensive Air Showers from Ultra High Energy Gluinos

We study the proposal that the cosmic ray primaries above the Greisen-Zatsepin-Kuzmin (GZK) cutoff are gluino-containing hadrons ($\tilde g$-hadrons). We describe the interaction of $\tilde g$-hadrons with nucleons in the framework of the Gribov-Regge approach using a modified version of the hadronic interaction model QGSJET for the generations of Extensive Air Showers (EAS). There are two mass windows marginally allowed for gluinos: m_{\tilde g}\lsim 3 GeV and 25\lsim m_{\tilde g}\lsim 35 GeV. Gluino-containing hadrons corresponding to the second window produce EAS very different from the observed ones. Light $\tilde g$-hadrons corresponding to the first gluino window produce EAS similar to those initiated by protons, and only future detectors can marginally distinguish them. We propose a beam-dump accelerator experiment to search for $\tilde g$-hadrons in this mass window. We emphasize the importance of this experiment: it can discover (or exclude) the light gluino and its role as a cosmic ray primary at ultra high energies.Comment: 27 pages latex, 13 eps figure

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. METHODS: CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed. The population studied comprised subgroups of patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease. Patients were followed for 1 to 3 years. FINDINGS: 19,185 patients, with more than 6300 in each of the clinical subgroups, were recruited over 3 years, with a mean follow-up of 1.91 years. There were 1960 first events included in the outcome cluster on which an intention-to-treat analysis showed that patients treated with clopidogrel had an annual 5.32% risk of ischaemic stroke, myocardial infarction, or vascular death compared with 5.83% with aspirin. These rates reflect a statistically significant (p = 0.043) relative-risk reduction of 8.7% in favour of clopidogrel (95% Cl 0.3-16.5). Corresponding on-treatment analysis yielded a relative-risk reduction of 9.4%. There were no major differences in terms of safety. Reported adverse experiences in the clopidogrel and aspirin groups judged to be severe included rash (0.26% vs 0.10%), diarrhoea (0.23% vs 0.11%), upper gastrointestinal discomfort (0.97% vs 1.22%), intracranial haemorrhage (0.33% vs 0.47%), and gastrointestinal haemorrhage (0.52% vs 0.72%), respectively. There were ten (0.10%) patients in the clopidogrel group with significant reductions in neutrophils (< 1.2 x 10(9)/L) and 16 (0.17%) in the aspirin group. INTERPRETATION: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death. The overall safety profile of clopidogrel is at least as good as that of medium-dose aspirin